389results about How to "Achieve early diagnosis" patented technology

The invention discloses a magnetic nano-grade material with a cell-targeting property, and a biomedical application thereof. The magnetic nano-grade material can be specifically bound with highly expressed transferrin receptors on tissue cell surfaces, and can enter the cells. The material can be bound with various high-transferring-receptor-expression tissue cells with broad spectrum and specificity, such that high-efficiency cell targeting property can be realized on animal models. The material can be used as a magnetic resonance contrast agent and a fluorescent molecular probe in disease diagnosis, and can be used as a medicine carrier in disease treatment.

The invention discloses a short circuit fault self-detection method in a single battery. The method comprises the following steps of: S1, building a first-order equivalent circuit model of the battery, determining a function relation between a state of charge (SOC) and an open-circuit voltage (OCV), and recognizing model parameters, S2, measuring load current and terminal voltage of the battery inreal time, S3, calculating ampere-hour increments at adjacent moments, estimating the SOC of the battery online by adopting a closed-loop state observer, and calculating an internal short circuit current according to the obtained ampere-hour increments and an SOC change value, S4, filtering the estimated internal short circuit current, and identifying the internal short circuit resistance of thebattery online by adopting a recursive least square method with an adaptive forgetting factor according to the filtered internal short circuit current and load voltage. According to a preset internalshort circuit resistance threshold, the internal short circuit state of the battery is compare3d and judged. Online identification of the short circuit resistance in the single battery can be realizedonly by measuring the terminal voltage and the load current of the single battery, and other single battery information in the battery pack is not needed.

The invention belongs to the technical field of biology and discloses a group of circRNA markers for early diagnosis of lung adenocarcinoma and application thereof. The circRNA marker disclosed by the invention comprises four kinds of circRNA, namely circRNA-100323, circRNA-69774, circRNA-403738 and circRNA-404449. The invention has the beneficial effects that a group of novel molecular bio-markers with diagnostic values on lung adenocarcinoma are provided. According to verifications of clinical sample cases, the group of circRNA markers have high diagnostic specificity and sensitivity on early diagnosis of lung adenocarcinoma.

The invention discloses application of MYOZ1 in diagnosing and treating parkinsonism, belonging to the technical field of new application of genes. The experiment proves that the MYOZ1 gene expression in the blood of a parkinsonism patient is enhanced as compared with a normal person, which indicates that the MYOZ1 expression level in the blood can be detected to diagnose whether a subject suffers from parkinsonism. The in-vitro MTT experiment detect that the MYOZ1 gene expression is not beneficial to growth of human neuroblastoma cells. Therefore, the MYOZ1 has favorable development and application prospects in preparing products for diagnosing and treating parkinsonism.

The invention relates to a polypeptide immunoassay kit, which comprises a protein G or protein A agarose serving as a solid phase carrier, a purified serum polypeptide antibody and PBS buffer solution. The invention also relates to a polypeptide immunomic spectrometry analysis method, which comprises the following steps: coupling a purified serum antibody with a proper solid carrier; allowing the coupled product to bond with a polypeptide marker antigen specifically, and separating the antigen from the carrier by using eluent; and finally, detecting polypeptide antigen in the eluent by high-pass matrix-assisted laser desorption / ionization time of flight mass spectrometry (MALDI-TOFMS). Thus, the complete immunomic spectrometry analysis method is established.

The invention relates to a fire detection, prevention and control system of an electronic control cabinet. The fire detection, prevention and control system comprises a data acquisition device, a fire extinguishing device and a main control device which are arranged in an electronic control cabinet body, wherein the data acquisition device is used for acquiring detection data of each detection node in the electronic control cabinet in real time, and transmitting the detection data to the main control device; the fire extinguishing device is used for accepting a control signal sent by the main control device, and carrying out fire control and processing on an area with a fire early warning; a fire extinguishing control module is used for sending a control signal to the fire extinguishing device according to the instruction of a CPU (central processing unit) core module. The invention further discloses a control method based on the system. The control method comprises the following steps: transmitting the CO and smoke concentration acquired in real time to the CPU core module; processing by a pre-detection data filter model to obtain a characteristic extraction value; if fire early warning standards are met, sending an early warning or starting the fire extinguishing device. The fire detection, prevention and control system and the control method disclosed by the invention are capable of performing real-time detection on a small space such as the electronic control cabinet, eliminating fire in the bud, and reducing the false alarm rate of fire early warning.

The invention relates to a drill pump error detection and diagnostic method based on a kinetic model. The method comprises the following steps of: 1, measuring a vibration signal and a pump stroke signal of a drill pump; 2, performing elementary section processing on the vibration signal according to a pump stroke period; 3, separating various characteristic signal components of the vibration signal of the drill pump to realize qualitative diagnosis on the errors of the drill pump; 4, performing characteristic parameter counting analysis on time domains and frequency domains of sub-section vibration signals of which attributes are determined to build actual measurement drill pump state vectors; 5, building the kinetic model of the drill pump; 6, optimizing and matching the actual measurement drill pump state vectors and the vectors in error characteristic matrixes in the drill pump system; and 7, displaying error detection and diagnosis results of the drill pump. With the adoption of the method, various characteristic information of the errors of the drill pump can be accurately and subtly extracted and reflected, the steady recognition and the qualitative diagnosis on the errors of the drill pump are realized, and the detection and the early warning of the running state of the drill pump are supplied in time so as to turn scheduled maintenance into on-condition maintenance.

The invention discloses an OSCC (oral squamous cell carcinoma) biomarker and an application thereof. The biomarker is XIRP2, an experiment proves that an XIRP2 gene expresses up regulation in OSCC tissue, and the silent XIRP2 gene can reduce transcription and translation of the gene to inhibit excessive proliferation of OSCC cells. The invention provides the application of the gene or an expression product of the gene in diagnosis and treatment of OSCC.

The invention provides a human papillomavirus HPV DNA fragment, a mix primer for human papillomavirus HPV DNA detection and / or parting and application thereof. The mixed primer can specifically amplify to obtain one or a plurality of DNA sequences from HPV6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 33, HPV 35, HPV 39, HPV 40, HPV 42, HPV 43, HPV 44, HPV45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 66, HPV 68, HPV 70, HPV 72, HPV 73, HPV 81, HPV 82 and HPV 83, can be used for the human papillomavirus HPV DNA detection and / or parting and prepared into a PCR kit. The invention can detect common types of HPV at a time, greatly improve the HPV detection efficiency, overcome the defect of missed detection of latent infection by a serology and IHC detection method, realize early diagnosis of HPV diseases, and is suitable for clinical HPV gene detection and parting and guides prevention and cure of cervical carcinoma.

The invention discloses a design way of primers for in-vitro qualitative detection of newborn inherited metabolic disease genes. The design way comprises the following steps: (1) acquiring relevant disease-causing gene information of inherited diseases: acquiring the relevant disease-causing gene information, including gene location information and mutation site information of a plurality of inherited diseases through an OMIM (Online Mendelian Inheritance in Man) database, and acquiring exon and intron information of relevant genes from an NCBI (National Center for Biotechnology Information) database according to the obtained gene information; (2) designing primers specific to the relevant genes: designing corresponding specific primers F1 and R1 specific to an exon and an exon-intron combination area of each gene. The invention also discloses the first-round PCR (Polymerase Chain Reaction) primer sequence list of syndromic deafness, a first-round PCR primer list of G6PD genes, and a first-round PCR primer sequence list of SLC12A3 genes. The primers can be used for detecting relevant genes of 22 types of common newborn inherited diseases.

The invention discloses a gene BPIFB1 and an expression product thereof. The gene BPIFB1 is a molecular marker for tongue squamous cell carcinoma early diagnosis. The gene BPIFB1 and the expression product have the advantages that as proved by QPCR (quantitative polymerase chain reaction), the gene BPIFB1 can be differently expressed in tongue squamous cell carcinoma tissues and para-carcinoma tissues and can be used as an indicator for tongue squamous cell carcinoma early diagnosis; the gene BPIFB1 and the expression product can be used as targets for treating tongue squamous cell carcinoma and can be used for guiding research and development of new medicines.

The invention discloses an LYPD3 gene and an expression product thereof both of which can serve as molecular markers for diagnosing osteoporosis. According to the LYPD3 and the expression product disclosed by the invention, a QPCR (quantitative polymerase chain reaction) experiment and a Western blot experiment provide that the LYPD3 gene has expression difference in blood or bone tissues of a normal person and an osteoporosis patient and can be used as an index for early diagnosis of the osteoporosis. In addition, the invention also discloses the LYPD3 gene and the expression product thereof both of which can serve as targets for diagnosing the osteoporosis and be used for guiding the research and development of novel medicaments.

The invention relates to a bispecific antibody of resisting PSMA / FITC (prostate specific membrane antigen / fluorescein isothiocyanate) for early diagnosis and treatment of a prostatic cancer. A single-chain antibody about the PSMA has been reported more at present, but the bispecific antibody of resisting the PSMA / FITC is researched less. The bispecific antibody related to the invention has a full-length nucleotide sequence shown in SEQ ID No.5. The bispecific antibody is produced by a gene recombination technology, and is convenient to produce and prepare at a large scale, small in molecular weight of an antibody, and strong in penetrating power of tumor tissue; micromolecule antibody can easily achieve the diseased region aiming at the anatomical features that the prostate tissue has thick prostate envelope; and treatment and early diagnosis of the prostatic cancer can be achieved by drugs carried by hapten or a marker by combining with prostatic cancer cells of the diseased region by a pre-targeting technology.

The invention discloses PLAC1 (placenta-specific 1) genes which can serve as a molecular marker for early diagnosis of osteoarthritis. Expressions of the PLAC1 genes in synovial tissue of a normal person and a patient suffering from osteoarthritis prove to be different in terms of the transcriptional level and the protein level, and accordingly, the disease risk and the disease state of a subject can be judged according to the identified expression level of the PLAC1 genes. Additionally, experiments prove that interference to expression of the PLAC1 genes or inhibition on the function of PLAC protein can inhibit proliferation of synovial cells, and a new target is provided for development of medicines for treating osteoarthritis clinically.

The invention discloses an osterarthritis diagnosis marker which refers to MTUSI gene and expression products thereof. According to gene chip and protein immunization tests, expressions of the MTUSI gene and expression products thereof are lowered in blood and bone tissue of osterarthritis patients as compared with those of the normal; thus, products for diagnosis of osterarthritis can be developed and can be applied to testing expression level of the MTUSI gene or expression products thereof. According to experiment in vitro, bone cell proliferation can be improved by over-expression of the MTUSI gene, and accordingly the MTUSI gene and the expression products thereof can be applied to development of medicines for treating osterarthritis.

A process for earlierly detecting pine nematosis includes inoculating the disc fungus (Ps0202) or other microbial fungi on culture medium, drilling circular hole on the pine trunk to be detected, inserting the test tube containing said fungi in said hole, staying it in the hole for 3-5 days, and determining by microscope. Its advantages are easy operation and high sensitivity.

The invention provides recombined II-type herpes simplex virus. In the virus, ICP34.5 gene of a wild II-type herpes simplex virus HG52 strain is excluded, and a fluorescent protein expression box is inserted in the gene group. The invention also provides a preparation method of the recombined II-type herpes simplex virus, the application of the recombined II-type herpes simplex virus in preparation of the drug for diagnosing tumours, and a tumour diagnostic reagent kit with the recombined II-type herpes simplex virus. In the recombined II-type herpes simplex virus disclosed by the invention, the ICP34.5 gene is excluded, so that the recombined II-type herpes simplex virus can selectively grow and breed in tumour cells, the recombined II-type herpes simplex virus is inserted in the fluorescent protein expression box and can give out fluorescence in tumour cells, so that the tumour diagnostic reagent kit with the recombined II-type herpes simplex virus can quickly, accurately, sensitively and broadly detect whether a sample to be detected contains tumour cells or not.

The invention discloses a nucleic acid analysis method based on a constant-temperature cross-catalyzed nuclease reaction. A metastable hairpin in an HCR amplifier is activated by a target to be openedautonomously and continuously; a double-stranded DNA nanowire containing a large amount of DNAzyme is generated; and the DNAzyme continuously catalyzes a shearing substrate to release a large amountof new initiation chains to reversely activate an HCR reaction. Due to the facts that the DNAzyme can continuously accumulate HCR initiation chains and HCR can continuously assemble a large amount ofDNAzyme, the cross-catalytic amplification reaction can convert the molecular recognition process into significantly amplified signals to be output. The R-HCR amplifier can be easily combined with anauxiliary sensing module to be developed into a universal sensing system, and ultra-sensitive in-vitro detection and intracellular imaging of single-molecule miRNA are successfully achieved. The nucleic acid analysis method provided by the invention has wide application prospect in the aspect of in-vivo detection of trace biomarkers in cytobiology and clinical diagnosis.

The invention discloses application of an EPB41L4B gene in diagnosis and treatment of a Parkinson disease. It is proved by experiments that compared with a normal person, expression of the EPB41L4B gene in the blood of a Parkinson disease patient is up-regulated, and it is shown that whether a subject suffers from the Parkinson disease or not can be diagnosed according to the expression level of EPB41L4B in the blood. According to the research results of the application of the EPB41L4B gene in the diagnosis and treatment of the Parkinson disease, the EPB41L4B can further be used for preparing a drug for treating the Parkinson disease. According to the application of the EPB41L4B gene in the diagnosis and treatment of the Parkinson disease, the sensibility and the specificity of Parkinson disease diagnosis are greatly improved, and meanwhile a new target is provided for gene treatment of the Parkinson disease.

The invention provides a diagnostic kit for detecting active pulmonary tuberculosis. The kit consists of an RNA extract buffer solution, a specific serum miRNA composition for the active pulmonary tuberculosis, internal reference reverse transcription primers, polymerase chain reaction (PCR) primers and a fluorescent quantitative reverse transcription-polymerase chain reaction (RT-PCR) reaction solution, wherein the specific serum miRNA composition for the active pulmonary tuberculosis consists of four differential expression serum miRNAs, namely hsa-miR-29c, hsa-miR-22, hsa-miR-320b and hsa-miR-101. By using the specific serum miRNAs composition for the active pulmonary tuberculosis to detect the active pulmonary tuberculosis on the serum miRNAs level, the sensitivity is 90.2 percent, and the specificity is 75.0 percent; and the kit has early-stage diagnostic value for the active pulmonary tuberculosis, and can realize early warning and early diagnosis of the active pulmonary tuberculosis.

The invention provides an anti-swine SC protein monoclonal antibody and an application of the monoclonal antibody in preparing a mycoplasma hyopneumoniae SIgA antibody ELISA detection kit, and relates to the technical field of animal virological and epizootiological detection. The anti-swine SC protein monoclonal antibody is secreted by a hybridoma cell strain 4H11 and the collection number of the anti-swine SC protein monoclonal antibody is CCTCC NO: C201526. The invention also discloses the monoclonal antibody and the application of the monoclonal antibody in preparing the mycoplasma hyopneumoniae SIgA antibody ELISA detection kit. The kit has high specificity, high stability and high sensitivity; a detection sample can be sampled conveniently; and the kit is capable of distinguishing porcine mycoplasma pneumonia inactivated vaccine immunization and natural infection, and can be applied to the early diagnosis of pneumonic porcine mycoplasma infection and the evaluation of the immune effect after attenuated live vaccine immunization.

The invention relates to an oil gas well down-hole fault diagnosis system and method. The diagnosis system is provided with a well drilling liquid inlet flow sensor, a well drilling liquid outlet flow sensor, a pressure sensor, a multi-channel signal collecting and sending device, a multi-channel signal receiving device and a computer system. The well drilling liquid inlet flow sensor is fixed on a ground manifold or a stand pipe. The well drilling liquid outlet flow sensor is fixed at a well drilling liquid backflow pipe or a mud ditch at a well opening of an oil gas well. The pressure sensor is arranged on the stand pipe. The multi-channel signal collecting and sending device is arranged on a drilling table of a well frame. Down-hole fault forecasting, locating and quantification diagnosis can be achieved, the accuracy and the identifying effect of fault diagnosis are greatly improved, changing of well drilling liquid flow and pressure is grasped timely and accurately, early-stage diagnosis of well leakage, well kicking and drilling rig washout is achieved, cost is low, mounting is convenient, a mounting position is reasonable, and the safety factor is high.

The invention provides a RNA probe capable of simultaneously detecting multiple neonatal hereditary diseases and a qualitative detection method in vitro of multiple neonatal genetic metabolic diseases, and the detection method provided by the invention is used for reducing the detection cost. Specifically, the invention discloses a RNA probe capable of simultaneously detecting multiple neonatal hereditary diseases, and the design method of the RNA probe comprises the following steps: 1) obtaining exon regions of genes corresponding to the neonatal genetic metabolic diseases; 2) regulating an oligonucleotide design principle. 1760 oligonucleotide sequences of the RNA probe provided by the invention are specifically as shown in table 1. The invention further provides a kit containing the RNA probe, and the kit can be used for simultaneously detecting multiple neonatal hereditary diseases.

The invention discloses an application of miR-3613 as a miRNA marker in distinguishing metastasis and non-metastasis of lung squamous carcinoma. Accordingly, the miR-3613 can be used for developing products for diagnosing lung squamous carcinoma metastasis and drugs for treating lung squamous carcinoma metastasis. The research result of the invention provides a theoretical basis for making individual-based treatment schemes by clinical physicians and can provide a new drug target for developing lung squamous carcinoma drugs.

Application of cfDNA in non-invasive diagnosis of early breast cancer The present invention discloses an application of cfDNA in non-invasive diagnosis of early breast cancer, a cfDNA marker with relatively high sensitivity and specificity for diagnosing breast cancer and a product for diagnosing breast cancer prepared based on the marker, and at the same time a method for screening cancer markers.

The invention discloses a CERS2 (ceramide synthase 2) gene and its expression product serving as a molecular marker for treating osteoporosis. Judgment may be given to whether a patient with osteoporosis or a treatment subject has the risk of suffering from osteoporosis, by detecting CERS2 gene and its expression product contents of bone tissues. The study on proliferation of osteoblasts cultured in vitro discovers that the expression inhibition of the CERS2 gene may promote the proliferation of the osteoblasts and that the proliferation of the osteoblasts may also be promoted by inhibiting the function of CERS2 proteins, and results of the study show that the CERS2 gene and its expression product are potential drug targets for treating osteoporosis.

The invention discloses a kit for early diagnosis of bladder cancer and a method for preparing the kit, and relates to the field of biomedical immune analysis. The detecting kit, which is fast, sensitive, highly specific in the early diagnosis of the bladder cancer is created by detecting a tumor marker of the bladder cancer tumor marker, namely, abnormally glycosylated integrin AG-alpha3beta, in human urine by means of microplate chemiluminescence immunoassay. The kit provided by the invention has the advantages of simplicity, convenience, quickness, sensitivity, high specificity, stability and the like, can be applied to early screening of the bladder cancer in a routine examination and to tracking observation and prognostic evaluation of the bladder cancer, and can satisfy the need that the existing in-vitro diagnosis of the bladder cancer is lack in specific diagnosis method.

The invention relates to a method for preparing a multifunctional manganous manganic oxide nano-particle nuclear magnetic resonance contrast agent mediated by polyethyleneimine. The method comprises the following steps: preparing PEI modified Mn3O4 nano-particles by using a solvothermal method, and then separating and purifying the nano-particles; then, marking tracer molecule fluorescein isothiocyanate FI on the nano-particles; modifying polyethylene glycol PEG molecules on the amino of PEI; and finally, modifying targeted reagent folic acid FA molecules on the PEI through PEG modification and performing complete acetylation treatment to obtain the contrast agent. The contrast agent prepared in the invention can trace the phagocytosis condition of the cancer cells to nanoparticles in a cellular level, has a significant targeting function on a high-expression cancer cell strain of an FA receptor and can be used for achieving early diagnosis of cancer, meanwhile, since the preparation method of the contrast agent is simple and easy and the raw materials are cheap and easy to obtain, the contrast agent can be produced in large batches.

The embodiments of the present invention provide a shale gas fracturing downhole accident early diagnosis and alarm method and device. The method includes the following steps that: the on-line monitoring data of reference variables which reflect a shale gas fracturing downhole condition are acquired; the time window of the online data is set according to a preset width; the time window is dividedinto a plurality of time segments with the same width, and linear fitting is performed on the online monitoring data in each time segment, so that the linear relationship curve of the online monitoring data in each time segment can be correspondingly obtained; corresponding trend feature primitives are determined according to the slope of the linear relationship curve of each time segment, trend feature vectors are built according to the trend feature primitives; and the trend feature vectors are substituted into a preset accident classifier, so that accident types corresponding to the onlinemonitoring data can be predicted, and corresponding alarm information is sent. With the shale gas fracturing downhole accident early diagnosis and alarm method and device of the embodiments of the present invention adopted, shale gas fracturing downhole accident early diagnosis and alarm can be achieved.

The invention relates to an ocean platform vibration noise comfort monitoring device and an online monitoring method. The device comprises a data storage and analysis platform which is connected witha plurality of distributed test terminals through a switch; the input end of each distributed test terminal is connected with a sensor; a computer terminal is further included and connected with the data storage and analysis platform through the switch; the distributed test terminals collect data transmitted by sensors, convert time domain signals into frequency spectrum data and transmits the frequency spectrum data to the data storage and analysis platform; the data storage and analysis platform compares the frequency spectrum data with a preset limit value and historical data, and when thefrequency spectrum data exceeds the limit value, alarm is raised. According to the invention, vibration of equipment can cabins in an ocean platform as well as air noise are monitored in real time, sothat a vibration noise abnormity fault can be eliminated timely, and it is ensured that the platform meets the comfort requirement of ship-level symbols.